Insulin concerns and promises

Diabetes Care

Volumn 34, Issue 6, 2011, Pages

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; FATTY ACID; GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SOMATOMEDIN C RECEPTOR; SULFONYLUREA DERIVATIVE;

BLADDER CANCER; BLOOD GLUCOSE MONITORING; BODY MASS; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; COLON CANCER; CONFERENCE PAPER; CONTINUOUS INFUSION; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENDOMETRIUM CANCER; GLYCEMIC CONTROL; HEART INFARCTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LIPOTOXICITY; LIVER CANCER; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; PANCREAS CANCER; PROSTATE CANCER; RECTUM CANCER; REMISSION; SURVIVAL TIME; UNFOLDED PROTEIN RESPONSE; WAIST CIRCUMFERENCE;

ANIMALS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; NEOPLASMS; OBESITY;

EID: 80051970187     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-0591     Document Type: Conference Paper

References (64)

1. Calle E.E., Rodriguez C., Walker-Thurmond K., Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-1638 (Pubitemid 36459468)
2. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-578 (Pubitemid 351232031)
3. Johnson J.A., Bowker S.L. Intensive glycaemic control and cancer risk in type 2 diabetes: A meta-analysis of major trials. Diabetologia 2011;54:25-31
4. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005;293:194-202 (Pubitemid 40095870)
5. Stocks T., Rapp K., Bjørge T., et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): Analysis of six prospective cohorts. PLoS Med 2009;6:e1000201
6. Kaaks R., Toniolo P., Akhmedkhanov A., et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-1600
7. Ma J., Giovannucci E., Pollak M., et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-553 (Pubitemid 38559579)
8. Barone B.B., Yeh H.C., Snyder C.F., et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 2008;300:2754-2764
9. Lipscombe L.L., Goodwin P.J., Zinman B., McLaughlin J.R., Hux J.E. The impact of diabetes on survival following breast cancer. Breast Cancer Res Treat 2008;109:389-395 (Pubitemid 351644852)
10. Lipscombe L.L., Hux J.E., Booth G.L. Reduced screening mammography among women with diabetes. Arch Intern Med 2005;165:2090-2095 (Pubitemid 41434583)
11. Maruthur N.M., Bolen S.D., Brancati F.L., Clark J.M. The association of obesity and cervical cancer screening: A systematic review and meta-analysis. Obesity (Silver Spring) 2009;17:375-381
12. Bowker S.L., Majumdar S.R., Veugelers P., Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-258 (Pubitemid 44106500)
13. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52:1766-1777
14. Bowker S.L., Yasui Y., Veugelers P., Johnson J.A. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: Assessing effects of time-varying exposure. Diabetologia 2010;53:1631-1637
15. Thompson A.M., Church T.S., Janssen I., Katzmarzyk P.T., Earnest C.P., Blair S.N. Cardiorespiratory fitness as a predictor of cancer mortality among men with prediabetes and diabetes. Diabetes Care 2008;31:764-769
16. Bronkowski J. The Ascent of Man. Boston, MA, Little Brown & Co, 1973
17. Hemkens L.G., Grouven U., Bender R., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia 2009;52:1732-1744
18. Pocock S.J., Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet 2009;374:511-513
19. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based followup study in Sweden. Diabetologia 2009;52:1745-1754
20. Colhoun H.M.; SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009;52:1755-1765
21. Smith U., Gale E.A. Does diabetes therapy influence the risk of cancer? Diabetologia 2009;52:1699-1708
22. Rosenstock J., Fonseca V., McGill J.B., et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open-label study. Diabetologia 2009;52:1971-1973
23. Home P.D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009;52:2499-2506
24. ORIGIN press release regarding glargine insulin and cancer [article online], 2009. Available from www.ies.org.il/ORIGIN-Press-Release-050809.pdf. Accessed 26 March 2011
25. Ciaraldi T.P., Carter L., Seipke G., Mudaliar S., Henry R.R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: Comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001;86:5838-5847 (Pubitemid 33152632)
26. Mannucci E., Monami M., Balzi D., et al. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2010;33:1997-2003
27. Giovannucci E., Harlan D.M., Archer M.C., et al. Diabetes and cancer: A consensus report. Diabetes Care 2010;33:1674-1685
28. Garvey W.T., Olefsky J.M., Griffin J., Hamman R.F., Kolterman O.G. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985;34:222-234 (Pubitemid 15134779)
29. Utzschneider K.M., Prigeon R.L., Faulenbach M.V., et al. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels. Diabetes Care 2009;32:335-341
30. Godsland I.F., Jeffs J.A., Johnston D.G. Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004;47:1157-1166 (Pubitemid 39093312)
31. Boden G., Ruiz J., Kim C.J., Chen X. Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects. Am J Physiol 1996;270:E251-E258
32. Rossetti L., Smith D., Shulman G.I., Papachristou D., DeFronzo R.A. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515 (Pubitemid 17099657)
33. Paolisso G., Tagliamonte M.R., Rizzo M.R., et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 1998;41:1127-1132 (Pubitemid 28449076)
34. Kashyap S., Belfort R., Gastaldelli A., et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474 (Pubitemid 37210533)
35. Cusi K., Kashyap S., Gastaldelli A., Bajaj M., Cersosimo E. Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007;292:E1775-E1781 (Pubitemid 47084713)
36. Leung N., Sakaue T., Carpentier A., Uffelman K., Giacca A., Lewis G.F. Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 2004;47:204-213 (Pubitemid 38315356)
37. Poitout V., Robertson R.P. Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr Rev 2008;29:351-366 (Pubitemid 351679704)
38. Lupi R., Del Guerra S., Mancarella R., et al. Insulin secretion defects of human type 2 diabetic islets are corrected in vitro by a new reactive oxygen species scavenger. Diabetes Metab 2007;33:340-345 (Pubitemid 350030903)
39. Maedler K., Sergeev P., Ris F., et al. Glucoseinduced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-860
40. Hull R.L., Westermark G.T., Westermark P., Kahn S.E. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004;89:3629-3643 (Pubitemid 39071447)
41. Hull R.L., Zraika S., Udayasankar J., Aston-Mourney K., Subramanian S.L., Kahn S.E. Amyloid formation in human IAPP transgenic mouse islets and pancreas, and human pancreas, is not associated with endoplasmic reticulum stress. Diabetologia 2009;52:1102-1111
42. Bouche C., Lopez X., Fleischman A., et al. Insulin enhances glucose-stimulated insulin secretion in healthy humans. Proc Natl Acad Sci USA 2010;107:4770-4775
43. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760 (Pubitemid 351697950)
44. Kahn S.E., Lachin J.M., Zinman B., et al.; The ADOPT Study Group. Effects of rosiglitazone, glyburide, and metformin on b-cell function and insulin sensitivity in ADOPT. Diabetes 2011;60:1552-1560
45. Yoon K.H., Lee J.H., Kim J.W., et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-1688
46. Tanaka S., Horimai C., Katsukawa F. Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: A meta-analysis. Acta Diabetol 2003;40(Suppl. 1):S302-S304 (Pubitemid 37322782)
47. Nishi Y., Fukushima M., Suzuki H., et al. Insulin secretion and insulin sensitivity in Japanese subjects with impaired fasting glucose and isolated fasting hyperglycemia. Diabetes Res Clin Pract 2005;70:46-52 (Pubitemid 41207647)
48. Kuroe A., Fukushima M., Usami M., et al. Impaired beta-cell function and insulin sensitivity in Japanese subjects with normal glucose tolerance. Diabetes Res Clin Pract 2003;59:71-77 (Pubitemid 35461912)
49. Boyko E.J., Fujimoto W.Y., Leonetti D.L., Newell-Morris L. Visceral adiposity and risk of type 2 diabetes: A prospective study among Japanese Americans. Diabetes Care 2000;23:465-471 (Pubitemid 30185788)
50. Luk A.O., So W.Y., Ma R.C., et al.; Hong Kong Diabetes Registry. Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: A 5-year prospective analysis of the Hong Kong Diabetes Registry. Diabetes Care 2008;31:2357-2361
51. Zhao H.L., Lai F.M., Tong P.C., et al. Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes 2003;52:2759-2766 (Pubitemid 37339705)
52. Sakuraba H., Mizukami H., Yagihashi N., Wada R., Hanyu C., Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 2002;45:85-96 (Pubitemid 34118546)
53. Li Y., Xu W., Liao Z., et al. Induction of longterm glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-2602 (Pubitemid 39441457)
54. Park S., Choi S.B. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy. Diabetes Metab Res Rev 2003;19:124-130 (Pubitemid 36417196)
55. Chen H.S., Wu T.E., Jap T.S., Hsiao L.C., Lee S.H., Lin H.D. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008;31:1927-1932
56. Noh Y.H., Lee S.M., Kim E.J., et al. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion. Diabetes Metab Res Rev 2008;24:384-391
57. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
58. Sarwar N., Gao P., Seshasai S.R., et al.; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
59. Gerstein H.C., Santaguida P., Raina P., et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007;78:305-312 (Pubitemid 350030320)
60. Brunner E.J., Shipley M.J., Witte D.R., Fuller J.H., Marmot M.G. Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care 2006;29:26-31 (Pubitemid 44033426)
61. Selvin E., Steffes M.W., Zhu H., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
62. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
63. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
64. Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008;155:26-32